Reference is made to the stock exchange announcement made by Zelluna ASA (the
"Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares
in the Company in a private placement (the "Private Placement"), divided on a
first tranche of 3,729,774 new shares ("Tranche 1") and a second tranche of
1,770,226 new shares ("Tranche 2"). Reference is further made to the stock
exchange announcement made by the Company on 25 November 2025 announcing that an
extraordinary general meeting of the Company had resolved, amongst other things,
to issue the new shares in Tranche 2 of the Private Placement. 

Following the issuance of the Tranche 2 shares, Takeda Ventures, Inc.'s
ownership interest in the Company will cross below 5 per cent. 

The reduction in ownership is due to dilution as result of the Private
Placement. 

Takeda Ventures, Inc. holds 1,238,935 shares in the Company, equal to approx.
4.72 per cent of the shares and votes in the Company following completion of
Tranche 2 and the Private Placement. Takeda Ventures, Inc. is ultimately owned
and controlled by Takeda Pharmaceutical Company Limited.

This disclosure is made pursuant to Section 4-2 of the Norwegian Securities
Trading Act.